Training activity information
Details
Select, perform and interpret diagnostic techniques for the investigation of acute lymphoblastic leukaemia (ALL) in paediatric and adult populations
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Morphological features associated with ALL
- The sample type required and the preanalytical variables affecting results
- Clinical presentations and other investigations
- National and international guidelines
- WHO classification
- Local SOPs
- Quality assurance
- Prioritisation and communication of results
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What background knowledge of the classification, diagnostic criteria, and relevant laboratory techniques for paediatric and adult ALL, including the importance of immunophenotyping and cytogenetics, is needed?
- What insights do you hope to gain regarding the differences in diagnostic approaches and the significance of specific markers in paediatric versus adult ALL? What is your current understanding of the key diagnostic features and prognostic factors in ALL?
- How will you prepare for this activity (e.g., reviewing age-specific diagnostic guidelines, understanding risk stratification)? What potential difficulties might you face in selecting the most appropriate techniques or interpreting the results considering age-related differences, and how will you plan to address these?
- How do you feel about investigating ALL in both children and adults?
In action
- Considering the age of the patient and initial findings, what specific diagnostic techniques for ALL are you selecting to perform? What are the key differences in the diagnostic approach for paediatric and adult ALL that you are keeping in mind?
- As you analyse morphology, immunophenotyping, and cytogenetic/molecular data, how are you integrating these results to classify the ALL and identify prognostic markers in real-time? Are there any conflicting results? How are you resolving these?
- Are you aware of the relevant classification systems (e.g., WHO) and their implications for prognosis and treatment as you interpret the findings?
- Are you considering the need for communication with clinical teams regarding urgent findings?
On action
- What were the key clinical and peripheral blood findings that raised suspicion for ALL in the paediatric and/or adult case(s) you investigated?
- What specific diagnostic techniques (morphology, immunophenotyping, cytogenetics, molecular) were selected and (where applicable) performed?
- What were the key morphological features observed in the bone marrow aspirate and peripheral blood?
- What were the significant findings from immunophenotyping, cytogenetic, and molecular studies?
- Were there any notable differences between the paediatric and adult cases?
- What are the diagnostic criteria for ALL according to current guidelines (e.g., WHO classification)?
- Are there differences in the diagnostic approach or criteria for paediatric versus adult ALL?
- What are the characteristic morphological, immunophenotypic, cytogenetic, and molecular features of different subtypes of ALL in both age groups?
- How do these findings inform prognosis and risk stratification in paediatric and adult ALL?
- What are the challenges in diagnosing and classifying ALL, and how do these challenges potentially differ between paediatric and adult cases?
- How will this experience enhance your ability to investigate and interpret results for suspected ALL in both paediatric and adult populations?
- What are the key resources and guidelines, including age-specific considerations, that you will refer to in future practice?
- How will you contribute to the integrated interpretation of results in the context of ALL, considering potential age-related differences?
Beyond action
- Have you been involved in the investigation of other cases of ALL since this training activity, considering the differences in presentation and prognosis between paediatric and adult patients? How did the diagnostic work-up vary?
- Have you reviewed your reflect-on-action notes from this training activity? Has your understanding of the immunophenotypic and molecular characteristics used to classify ALL subtypes evolved?
- Can you recall MDT discussions where the complex diagnostic landscape of ALL, including risk stratification, was discussed? What were the key laboratory contributions?
- Have you reviewed current guidelines (e.g., WHO classification, MRC ALL clinical trials rationale) related to the diagnosis and risk stratification of ALL since this training activity?
- Has this training activity enhanced your ability to select and interpret the appropriate laboratory tests, including immunophenotyping and molecular studies, for the diagnosis and classification of ALL?
- Do you now have a better understanding of the differences in the biological features and prognostic factors of ALL in different age groups?
- Has this experience influenced your understanding of the role of measurable residual disease (MRD) monitoring in the management of ALL?
- Have the analytical and interpretative skills applied in this training activity been transferable to the investigation of other lymphoid neoplasms?
- How will your experience in diagnosing and classifying ALL prepare you for managing these aggressive leukaemias and understanding the rationale behind different treatment protocols?
- Will your ability to accurately interpret complex diagnostic data contribute to informed clinical decision-making and risk-adapted therapy for patients with ALL?
- How might this experience support your potential involvement in research or the development of novel diagnostic or prognostic markers in ALL?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 3 |
Outcome
Perform a range of laboratory and molecular testing techniques to diagnose and monitor treatment of haematological malignancy in the correct clinical context, including the interpretation and reporting of results. |
| # 4 |
Outcome
Interpret and comply with national and international guidelines on the diagnosis and management of haematological cancer. |
| # 7 |
Outcome
Perform quality assurance and control tasks across the range of investigations. |